2023
Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
de Assis F, Hoehn K, Zhang X, Kardava L, Smith C, Merhebi O, Buckner C, Trihemasava K, Wang W, Seamon C, Chen V, Schaughency P, Cheung F, Martins A, Chiang C, Li Y, Tsang J, Chun T, Kleinstein S, Moir S. Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine. Cell Reports 2023, 42: 112780. PMID: 37440409, PMCID: PMC10529190, DOI: 10.1016/j.celrep.2023.112780.Peer-Reviewed Original ResearchConceptsMemory B cellsB cell receptorB cellsAtypical memory B cellsInfection-naïve individualsTwo-dose SARSSARS-CoV-2 mRNAB cell responsesAntibody-secreting cellsMonth 6Protective immunityCell responsesCell receptorClonal expansionImmunoglobulin GEarly timepointsLater timepointsPlasmablastsVaccinationCD71TimepointsSurface proteinsCellsMultimodal single-cell analysisMRNA
2022
Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children
Xu Q, Milanez-Almeida P, Martins A, Radtke A, Hoehn K, Oguz C, Chen J, Liu C, Tang J, Grubbs G, Stein S, Ramelli S, Kabat J, Behzadpour H, Karkanitsa M, Spathies J, Kalish H, Kardava L, Kirby M, Cheung F, Preite S, Duncker P, Kitakule M, Romero N, Preciado D, Gitman L, Koroleva G, Smith G, Shaffer A, McBain I, McGuire P, Pittaluga S, Germain R, Apps R, Schwartz D, Sadtler K, Moir S, Chertow D, Kleinstein S, Khurana S, Tsang J, Mudd P, Schwartzberg P, Manthiram K. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. Nature Immunology 2022, 24: 186-199. PMID: 36536106, PMCID: PMC10777159, DOI: 10.1038/s41590-022-01367-z.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAntibodies, ViralChildCOVID-19HumansPalatine TonsilPandemicsSARS-CoV-2ConceptsT cell receptorImmune responseGerminal centersPrevious SARS-CoV-2 infectionSARS-CoV-2 infectionB-cell receptor sequencingTissue-specific immunityCell receptor sequencingAdaptive immune responsesUpper respiratory tractMemory B cellsT cell clonotypesSite of infectionSARS-CoV-2Pharyngeal lymphoid tissuePeripheral bloodLymphocyte populationsLymphoid tissueRespiratory tractCell clonotypesAdaptive immunityB cellsCDR3 sequencesAdenoidsCell receptorConsidering innate immune responses in SARS-CoV-2 infection and COVID-19
Diamond M, Lambris J, Ting J, Tsang J. Considering innate immune responses in SARS-CoV-2 infection and COVID-19. Nature Reviews Immunology 2022, 22: 465-470. PMID: 35788185, PMCID: PMC9252555, DOI: 10.1038/s41577-022-00744-x.Peer-Reviewed Original ResearchEarly human B cell signatures of the primary antibody response to mRNA vaccination
Kardava L, Rachmaninoff N, Lau W, Buckner C, Trihemasava K, Blazkova J, de Assis F, Wang W, Zhang X, Wang Y, Chiang C, Narpala S, McCormack G, Liu C, Seamon C, Sneller M, O’Connell S, Li Y, McDermott A, Chun T, Fauci A, Tsang J, Moir S. Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2204607119. PMID: 35759653, PMCID: PMC9282446, DOI: 10.1073/pnas.2204607119.Peer-Reviewed Original ResearchConceptsMemory B cellsAntibody responseDose 2MBC populationsB cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Durability of antibodiesSubsequent antibody levelsB cell signaturesIgG antibody responsePrimary antibody responseSyndrome coronavirus 2Weak antibody responseMessenger RNA vaccinesPlasmablast frequencyFirst doseMRNA vaccinationMonth 6Antibody levelsProtective immunitySecond dosesAntibody titersCoronavirus 2Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19
Sacco K, Castagnoli R, Vakkilainen S, Liu C, Delmonte OM, Oguz C, Kaplan IM, Alehashemi S, Burbelo PD, Bhuyan F, de Jesus AA, Dobbs K, Rosen LB, Cheng A, Shaw E, Vakkilainen MS, Pala F, Lack J, Zhang Y, Fink DL, Oikonomou V, Snow AL, Dalgard CL, Chen J, Sellers BA, Montealegre Sanchez GA, Barron K, Rey-Jurado E, Vial C, Poli MC, Licari A, Montagna D, Marseglia GL, Licciardi F, Ramenghi U, Discepolo V, Lo Vecchio A, Guarino A, Eisenstein EM, Imberti L, Sottini A, Biondi A, Mató S, Gerstbacher D, Truong M, Stack MA, Magliocco M, Bosticardo M, Kawai T, Danielson JJ, Hulett T, Askenazi M, Hu S, Cohen J, Su H, Kuhns D, Lionakis M, Snyder T, Holland S, Goldbach-Mansky R, Tsang J, Notarangelo L. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nature Medicine 2022, 28: 1050-1062. PMID: 35177862, PMCID: PMC9119950, DOI: 10.1038/s41591-022-01724-3.Peer-Reviewed Original ResearchConceptsInflammatory syndromeSevere acute respiratory syndrome coronavirus 2Pediatric coronavirus disease 2019Acute respiratory syndrome coronavirus 2Robust type I interferon (IFN) responseRespiratory syndrome coronavirus 2Pediatric COVID-19Pediatric healthy controlsSignatures of inflammationMultisystem inflammatory syndromeTime of admissionSyndrome coronavirus 2Combination of HLAT cell clonotypesType I interferon responseCoronavirus disease 2019Multi-institutional studyCOVID-19Minority of childrenT cell activationI interferon responseType II IFNSubstantial morbidityCoronavirus 2PCR status
2021
Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children
Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, Li N, Liu Y, Shah A, Ravindra NG, Bishai J, Khan A, Lau W, Sellers B, Bansal N, Guerrerio P, Unterman A, Habet V, Rice AJ, Catanzaro J, Chandnani H, Lopez M, Kaminski N, Dela Cruz CS, Tsang JS, Wang Z, Yan X, Kleinstein SH, van Dijk D, Pierce RW, Hafler DA, Lucas CL. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 2021, 54: 1083-1095.e7. PMID: 33891889, PMCID: PMC8043654, DOI: 10.1016/j.immuni.2021.04.003.Peer-Reviewed Original ResearchConceptsMIS-C patientsDisease severityInflammatory syndromeTCR repertoireSARS-CoV-2-associated multisystem inflammatory syndromeAsymptomatic SARS-CoV-2 infectionSARS-CoV-2 infectionAdult COVID-19Post-infectious complicationsMultisystem inflammatory syndromeCytotoxicity genesHealthy pediatricImmune dysregulationMemory TActive infectionMyeloid dysfunctionPatientsSingle-cell RNA sequencingFlow cytometrySerum proteomicsRepertoire analysisElevated expressionSeverityAlarminsCOVID-19An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, Zarember KA, Alehashemi S, Oikonomou V, Desai JV, Canna SW, Shakoory B, Dobbs K, Imberti L, Sottini A, Quiros-Roldan E, Castelli F, Rossi C, Brugnoni D, Biondi A, Bettini LR, D’Angio’ M, Bonfanti P, Castagnoli R, Montagna D, Licari A, Marseglia GL, Gliniewicz EF, Shaw E, Kahle DE, Rastegar AT, Stack M, Myint-Hpu K, Levinson SL, DiNubile MJ, Chertow DW, Burbelo PD, Cohen JI, Calvo KR, Tsang JS, Consortium N, Su HC, Gallin JI, Kuhns DB, Goldbach-Mansky R, Lionakis MS, Notarangelo LD. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 2021, 6: e144455. PMID: 33232303, PMCID: PMC7821609, DOI: 10.1172/jci.insight.144455.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedAntiviral AgentsAzithromycinBiomarkersCalgranulin BCase-Control StudiesChemokine CCL2Chemokine CXCL9COVID-19Enzyme InhibitorsFemaleFerritinsGene Expression ProfilingHumansHydroxychloroquineImmunologic FactorsInterferon Type IInterferon-gammaInterleukin-1 Receptor-Like 1 ProteinInterleukin-10Interleukin-15Interleukin-2Interleukin-6LactoferrinLipocalin-2MaleMatrix Metalloproteinase 9Middle AgedMultivariate AnalysisNF-kappa BPrognosisReceptors, Tumor Necrosis Factor, Type ISARS-CoV-2Severity of Illness IndexVascular Endothelial Growth Factor Receptor-1ConceptsType I IFNI IFNSevere acute respiratory syndrome coronavirus 2Whole blood transcriptional signaturesAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Immune-based biomarkersCOVID-19 patientsSyndrome coronavirus 2Eventual disease outcomeTissue-resident cellsCoronavirus disease 2019COVID-19Type II IFNInflammatory signatureIL-10Clinical outcomesMultivariable analysisIL-15Aforementioned biomarkersCell subsetsCoronavirus 2IL-1αSoluble biomarkersInflammatory response